Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the comparative bioavailability of Test Product Dapagliflozin/metformin hydrochloride 5 mg/1000 mg film-coated tablets to Reference Product Xigduo 5 mg/1000 mg film-coated tablets in healthy adult male and female subjects under fed conditions.

2025-522254-39-00 Protocol 1019/25 Human pharmacology (Phase I) - Other Ended

Start 29 Sep 2025 · End 22 Oct 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 1019/25

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 32
Countries 1
Sites 1

Bioavailability study in healthy volunteers under fed conditions.

Key facts

Sponsor
Laboratorios Cinfa S.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
29 Sep 2025 → 22 Oct 2025
Decision date (initial)
2025-09-10
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Bioavailability study in healthy volunteers under fed conditions.

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Laboratorios Cinfa S.A.

Sponsor organisation
Laboratorios Cinfa S.A.
Address
Travesia De Roncesvalles 1, Olloki Olloki
City
Esteribar
Postcode
31699
Country
Spain

Scientific contact point

Organisation
Laboratorios Cinfa S.A.
Contact name
Rubén Rubén Estepa Sanz

Public contact point

Organisation
Laboratorios Cinfa S.A.
Contact name
Rubén Rubén Estepa Sanz

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 32 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Quinta-Analytica s.r.o.
Clinical Unit, Umelecka 305/1, Moravska Ostrava, Moravska Ostrava A Privoz

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2025-09-29 2025-10-22 2025-09-29 2025-10-11

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-08-08 Czechia Acceptable
2025-09-10
2025-09-10
2 SUBSTANTIAL MODIFICATION SM-1 2025-09-18 Czechia Acceptable 2025-09-22